title: Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder.
abstract: Twenty outpatients with locally advanced (inoperable) or metastatic transitional cell carcinomas of the bladder were treated with carboplatin (300 mg/m2 i.v., day 1) + methotrexate (40 mg/m2 days 1 and 8) + vinblastine (6 mg/m2 days 1 and 8) (CaMV), every 4 weeks. One patient died of disease progression before completing at least 2 cycles of chemotherapy. Seven patients (35%) obtained a partial response; 8 had disease stabilization (40%) and 4 progressed (20%). Median duration of response was 3 months (range: 3-9), and median overall survival was 12+ months (range: 1-18+). None of the patients suffered grade IV toxicities, and no nephro-, neuro-, or ototoxicity was observed.
authors.affiliation: Unità Operativa di Oncologia Medica, Ospedale S. Andrea, La Spezia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: M
authors.initials: M
authors.lastname: Landucci
authors.forename: F
authors.initials: F
authors.lastname: Vaira
authors.forename: A
authors.initials: A
authors.lastname: Vigani
authors.forename: G
authors.initials: G
authors.lastname: Bertelli
mesh_terms: D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D012074:Remission Induction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D008727:Methotrexate